Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 2/2017

01-02-2017 | Original Article – Cancer Research

The ratio of cancer cells to stroma after induction therapy in the treatment of non-small cell lung cancer

Authors: Masaki Goto, Masahito Naito, Koichi Saruwatari, Kakeru Hisakane, Motohiro Kojima, Satoshi Fujii, Takeshi Kuwata, Atsushi Ochiai, Shogo Nomura, Keiju Aokage, Tomoyuki Hishida, Junji Yoshida, Kohei Yokoi, Masahiro Tsuboi, Genichiro Ishii

Published in: Journal of Cancer Research and Clinical Oncology | Issue 2/2017

Login to get access

Abstract

Purpose

Induction therapy induces degenerative changes of various degrees in both cancerous and non-cancerous cells of non-small cell lung cancer (NSCLC). The effect of induction therapy on histological characteristics, in particular the ratio of residual cancer cells to non-cancerous components, is unknown.

Methods

Seventy-four NSCLC patients treated with induction therapy followed by surgery were enrolled. Residual cancer cells were identified using anti-pan-cytokeratin antibody (AE1/AE3). We analyzed and quantified the following three factors via digital image analysis; (1) the tumor area containing cancer cells and non-cancerous components (TA), (2) the total area of AE1/AE3 positive cancer cells (TACC), (3) the percentage of TACC to TA (%TACC). These factors were also analyzed in a matched control group (surgery alone, n = 80).

Results

The median TACC of the induction therapy group was significantly lower than that of the control group (p < 0.01). In addition, the median %TACC of the induction therapy group (5.9 %) was significantly lower than that of the control group (58.6 %) (p < 0.01). TACC had a strong positive correlation with TA in the control group (r = 0.93), but not in the induction therapy group. Conversely, TACC had a strong positive correlation with %TACC in the induction therapy group (r = 0.95), but not in the control group.

Conclusion

Unlike the control group, the smaller the total area of residual cancer cells, the higher residual tumor contained non-cancerous components in the induction group, which may be the characteristic histological feature of NSCLC after induction therapy.
Appendix
Available only for authorised users
Literature
go back to reference Bremnes RM et al (2011a) The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer. J Thorac Oncol 6:824–833. doi:10.1097/JTO.0b013e3182037b76 CrossRefPubMed Bremnes RM et al (2011a) The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer. J Thorac Oncol 6:824–833. doi:10.​1097/​JTO.​0b013e3182037b76​ CrossRefPubMed
go back to reference Junker K, Thomas M, Schulmann K, Klinke F, Bosse U, Muller KM (1997) Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histol Assess J Cancer Res Clin Oncol 123:469–477CrossRef Junker K, Thomas M, Schulmann K, Klinke F, Bosse U, Muller KM (1997) Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histol Assess J Cancer Res Clin Oncol 123:469–477CrossRef
go back to reference Liu-Jarin X, Stoopler MB, Raftopoulos H, Ginsburg M, Gorenstein L, Borczuk AC (2003) Histologic assessment of non-small cell lung carcinoma after neoadjuvant therapy. Mod Pathol 16:1102–1108CrossRefPubMed Liu-Jarin X, Stoopler MB, Raftopoulos H, Ginsburg M, Gorenstein L, Borczuk AC (2003) Histologic assessment of non-small cell lung carcinoma after neoadjuvant therapy. Mod Pathol 16:1102–1108CrossRefPubMed
go back to reference Martini N, Flehinger BJ (1987) The role of surgery in N2 lung cancer. Surg Clin N Am 67:1037–1049CrossRefPubMed Martini N, Flehinger BJ (1987) The role of surgery in N2 lung cancer. Surg Clin N Am 67:1037–1049CrossRefPubMed
go back to reference Neri S, Ishii G, Hashimoto H, Kuwata T, Nagai K, Date H, Ochiai A (2015) Podoplanin-expressing cancer-associated fibroblasts lead and enhance the local invasion of cancer cells in lung adenocarcinoma. Int J Cancer 137:784–796. doi:10.1002/ijc.29464 CrossRefPubMed Neri S, Ishii G, Hashimoto H, Kuwata T, Nagai K, Date H, Ochiai A (2015) Podoplanin-expressing cancer-associated fibroblasts lead and enhance the local invasion of cancer cells in lung adenocarcinoma. Int J Cancer 137:784–796. doi:10.​1002/​ijc.​29464 CrossRefPubMed
go back to reference Pisters KM, Kris MG, Gralla RJ, Zaman MB, Heelan RT, Martini N (1993) Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials. J Clin Oncol 11:1757–1762PubMed Pisters KM, Kris MG, Gralla RJ, Zaman MB, Heelan RT, Martini N (1993) Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials. J Clin Oncol 11:1757–1762PubMed
go back to reference van Meerbeeck JP et al (2007) Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non–small-cell lung cancer. J Natl Cancer Inst 99:442–450. doi:10.1093/jnci/djk093 CrossRefPubMed van Meerbeeck JP et al (2007) Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non–small-cell lung cancer. J Natl Cancer Inst 99:442–450. doi:10.​1093/​jnci/​djk093 CrossRefPubMed
go back to reference Yamane Y et al (2010) A novel histopathological evaluation method predicting the outcome of non-small cell lung cancer treated by neoadjuvant therapy: the prognostic importance of the area of residual tumor. J Thorac Oncol 5:49–55. doi:10.1097/JTO.0b013e3181c0a1f8 CrossRefPubMed Yamane Y et al (2010) A novel histopathological evaluation method predicting the outcome of non-small cell lung cancer treated by neoadjuvant therapy: the prognostic importance of the area of residual tumor. J Thorac Oncol 5:49–55. doi:10.​1097/​JTO.​0b013e3181c0a1f8​ CrossRefPubMed
Metadata
Title
The ratio of cancer cells to stroma after induction therapy in the treatment of non-small cell lung cancer
Authors
Masaki Goto
Masahito Naito
Koichi Saruwatari
Kakeru Hisakane
Motohiro Kojima
Satoshi Fujii
Takeshi Kuwata
Atsushi Ochiai
Shogo Nomura
Keiju Aokage
Tomoyuki Hishida
Junji Yoshida
Kohei Yokoi
Masahiro Tsuboi
Genichiro Ishii
Publication date
01-02-2017
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cancer Research and Clinical Oncology / Issue 2/2017
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-016-2271-8

Other articles of this Issue 2/2017

Journal of Cancer Research and Clinical Oncology 2/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.